Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Employees - 73,
CEO - Dr. Rene Russo BCPS, Pharm.D.,
Sector - Healthcare,
Country - US,
Market Cap - 76.79M
Altman ZScore(max is 10): -8.63, Piotroski Score(max is 10): 4, Working Capital: $25287000, Total Assets: $74658000, Retained Earnings: $-370660000, EBIT: -63571000, Total Liabilities: $53684000, Revenue: $7522000
AryaFin Target Price - $1.2 - Current Price $1.28 - Analyst Target Price $4.50
| Ticker | XLO |
| Index | - |
| Curent Price | 1.28 |
| Change | 36.46% |
| Market Cap | 76.79M |
| Average Volume | 406.11K |
| Income | -62.80M |
| Sales | 4.62M |
| Book Value/Share | 0.48 |
| Cash/Share | 1.02 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 73 |
| Moving Avg 20days | 26.33% |
| Moving Avg 50days | 26.51% |
| Moving Avg 200days | 31.86% |
| Shares Outstanding | 43.96M |
| Earnings Date | Nov 07 BMO |
| Inst. Ownership | 16.09% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 16.62 |
| Price/Book | 2.68 |
| Price/Cash | 1.25 |
| Price/FCF | - |
| Quick Ratio | 1.67 |
| Current Ratio | 1.67 |
| Debt/Equity | 0.40 |
| Return on Assets | -82.36% |
| Return on Equity | -170.96% |
| Return on Investment | -222.41% |
| Gross Margin | 62.40% |
| Ops Margin | -1388.44% |
| Profit Margin | -1359.37% |
| RSI | 65.43 |
| BETA(β) | -0.31 |
| From 52week Low | 161.22% |
| From 52week High | -33.68% |
| EPS | -1.72 |
| EPS next Year | -0.51 |
| EPS next Qtr | -0.22 |
| EPS this Year | 58.99% |
| EPS next 5 Year | - |
| EPS past 5 Year | -44.91% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 41.89% |
| Sales Y/Y | - |
| EPS Q/Q | 63.70% |
| Sales Q/Q | - |
| Sales Surprise | -30.91% |
| EPS Surprise | 10.82% |
| ATR(14) | 0.13 |
| Perf Week | 32.12% |
| Perf Month | 36.00% |
| Perf Quarter | 69.36% |
| Perf Year | 155.80% |
| Perf YTD | 132.73% |
| Target Price | 4.50 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer